Esketamine (Spravato) for Treatment-Resistant Depression

被引：5

作者：

Jalloh, Mohamed ^{[1
]}

机构：

[1] Touro Univ Calif, Coll Pharm, Vallejo, CA 94592 USA

来源：

AMERICAN FAMILY PHYSICIAN | 2020年 / 101卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Esketamine (Spravato) is an active isomer of ketamine that acts as an N-methyl-D-aspartate receptor antagonist.(1,2) The exact antidepressant mechanism is unknown, but it is labeled as adjunctive therapy for adults with treatment-resistant depression who are already taking an oral antidepressant.

引用

页码：339 / 340

页数：2

共 6 条

[1]

DailyMed, DRUG LAB INF SPRAV E

[2] Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial [J].

Daly, Ella J. ;

Trivedi, Madhukar H. ;

Janik, Adam ;

Li, Honglan ;

Zhang, Yun ;

Li, Xiang ;

Lane, Rosanne ;

Lim, Pilar ;

Duca, Anna R. ;

Hough, David ;

Thase, Michael E. ;

Zajecka, John ;

Winokur, Andrew ;

Divacka, Ilona ;

Fagiolini, Andrea ;

Cubala, Wieslaw J. ;

Bitter, Istvan ;

Blier, Pierre ;

Shelton, Richard C. ;

Molero, Patricio ;

Manji, Husseini ;

Drevets, Wayne C. ;

Singh, Jaskaran B. .

JAMA PSYCHIATRY, 2019, 76 (09) :893-903

[3]

Institute for Clinical and Economic Review, 2019, ESK TREATM TREATM RE

[4] Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials [J].

Khan, A ;

Khan, SR ;

Shankles, EB ;

Polissar, NL .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (06) :281-285

[5] Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States [J].

Ross, Eric L. ;

Zivin, Kara ;

Maixner, Daniel F. .

JAMA PSYCHIATRY, 2018, 75 (07) :713-722

[6]

U.S. Food and Drug Administration, 2019 M MAT PSYCH DRU

← 1 →